In Re: Modafinil Antitrust Litigation

E-Law Admin/ September 13, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

In Re: Modafinil Antitrust Litigation, 15-3475

In a putative class of twenty-two large and sophisticated corporations, most of which have multi-million dollar claims, alleging a global conspiracy involving Cephalon and all four generic defendants under 15 U.S.C. section 1, four separate conspiracies between Cephalon and each generic defendant under the same statute, and a monopolization claim against Cephalon under 15 U.S.C. section 2, the District Court’s class certification order is vacated where plaintiffs have not met their burden of showing that the numerosity requirement of Rule 23(a)(1) has been satisfied, and remanded for further consideration of whether joinder of all class members is impracticable.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/09/13



  • United States Third Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar